Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 59 peer-reviewed journal articles Updated
Radiology

Intraductal Breast Papillomatosis: A Patient Guide

At a Glance

Intraductal breast papillomatosis is a benign condition involving multiple growths inside the milk ducts. The choice between monitoring and surgical removal depends on whether atypia is present, whether the biopsy matches imaging, which lesion was sampled, any remaining abnormality, symptoms, and family history.

Intraductal breast papillomatosis is a benign (non-cancerous) condition where small, wart-like growths develop inside the milk ducts of the breast. While the word “tumor” may appear in your reports, these are not breast cancer; they are localized overgrowths of normal ductal cells [1][2]. Under a microscope, these growths are characterized by delicate, finger-like structures called fibrovascular cores that are supported by a healthy, two-layered lining of cells [3][2].

Doctors distinguish between a solitary papilloma (a single growth, often near the nipple) and papillomatosis (multiple growths, often deeper in the breast) [1][4]. Having multiple growths, or papillomatosis, often requires a more detailed evaluation by your care team. Because these growths can be scattered across different ducts, radiologists and pathologists work closely together to ensure that the small tissue samples taken during a biopsy truly represent the entire area seen on your imaging—a critical process known as radiology-pathology concordance [5][6]. A single benign sample establishes what was seen in the core, but it may not represent every other lesion in a breast with multifocal papillomatosis.

Understanding Your Results: Three Separate Questions

  1. What the biopsy shows: Is the sampled tissue a benign papilloma, or does it contain atypia or non-invasive cancer?
  2. The chance of an “upgrade”: What is the likelihood that the unsampled tissue nearby contains a more serious finding?
  3. Your future breast-cancer risk: How does this diagnosis, combined with your family history, affect your long-term risk?

The most important “branch point” in your care is whether your biopsy shows atypia, which means the cells have begun to look unusual even though they are not cancer [7]. If your results are “concordant” and show no atypia, you may have the option of active surveillance, where the area is monitored with regular imaging rather than surgery [8][9]. This decision depends on which lesion was sampled, biopsy method, residual imaging abnormality, and symptoms. However, if atypia is present, or if the biopsy results don’t quite match the imaging, your doctor will likely recommend excision (removal) to ensure no more serious changes are hiding nearby [10][11].

Living with papillomatosis means maintaining a proactive relationship with your breast health. While the immediate findings are benign, your care team will tailor a long-term monitoring plan to your specific results and family history [5][12]. This ongoing vigilance helps monitor for interval change and provides a clear path forward [13].

In this guide

6 chapters

01

Understanding Intraductal Breast Papillomatosis

Learn what intraductal breast papillomatosis means, how it differs from a solitary papilloma, and how atypia, biopsy results, and follow-up guide your care.

02

Symptoms, Imaging, and the Diagnostic Journey

Learn how intraductal breast papillomatosis causes symptoms, appears on imaging, and is confirmed by biopsy, including concordance and upgrade risk for patients.

03

Your Pathology Report: Decoding the Microscope

Learn how to read an intraductal breast papillomatosis pathology report, including atypia, DCIS, myoepithelial cells, biopsy details, and cancer staging terms.

04

Treatment Options: Monitoring vs. Removal

Learn when intraductal breast papillomatosis can be monitored or removed, how VAE and surgery differ, and what follow-up imaging and recovery may involve.

05

Location and Subtypes: Central, Peripheral, and Juvenile Papillomatosis

Learn how central, peripheral, and juvenile breast papillomatosis differ, including symptoms, biopsy accuracy, family history, and future breast cancer risk.

06

Long-Term Monitoring and Future Breast Health

Learn how to monitor intraductal breast papillomatosis, choose follow-up imaging, understand future breast-cancer risk, and recognize changes needing prompt care.

Common questions in this guide

Is intraductal breast papillomatosis cancer?
No. Intraductal breast papillomatosis is a benign condition in which multiple wart-like growths form inside the milk ducts, although the biopsy still needs to be checked for atypia or non-invasive cancer.
What does it mean if my biopsy says there is no atypia?
It means the cells in the sampled growth do not look unusually abnormal under the microscope. When this result agrees with the imaging and other clinical details, active surveillance may be an option instead of immediate excision.
Why might my doctor recommend removing a papilloma?
Excision may be recommended if atypia is present or if the biopsy does not match the imaging. Removing the area allows a pathologist to examine more tissue when a nearby, more serious change may not have been captured by the biopsy.
How are multiple breast papillomas checked after a biopsy?
Radiologists and pathologists compare the biopsy findings with mammogram or ultrasound results to decide whether the sample represents the abnormal area; this is called radiology-pathology concordance. Follow-up imaging is then tailored to the sampled lesion, any remaining abnormality, symptoms, and other risk information.
How does family history affect follow-up for papillomatosis?
Your care team considers the diagnosis and your family history when assessing future breast-cancer risk. These factors help tailor a long-term monitoring plan, but your personal follow-up schedule should come from your clinician.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on intraductal breast papillomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report clearly state that the growths were 'without atypia'?
  2. 2.Was my biopsy result formally reviewed and considered 'concordant' with what was seen on my mammogram and ultrasound?
  3. 3.Because I have multiple papillomas, how do we ensure the samples taken are representative of all the areas?
  4. 4.What are the specific benefits and risks for me choosing surveillance versus surgical removal?
  5. 5.If we choose surveillance, what is the recommended schedule and type of imaging for my follow-up?

References

References (13)
  1. 1

    Multiple Papillomas of the Breast: A Review of Current Evidence and Challenges.

    Rella R, Romanucci G, Arciuolo D, et al.

    Journal of imaging 2022; (8(7)) doi:10.3390/jimaging8070198.

    PMID: 35877642
  2. 2

    Papillary Neoplasms of the Breast: WHO Classification, Multimodality Imaging, and Radiologic-Pathologic Correlation.

    Thai JN, Vickery J, Boyraz B, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2025; (45(8)):e240091 doi:10.1148/rg.240091.

    PMID: 40674246
  3. 3

    Mutational Analysis of AKT1 and PIK3CA in Intraductal Papillomas of the Breast with Special Reference to Cellular Components.

    Mishima C, Kagara N, Ikeda JI, et al.

    The American journal of pathology 2018; (188(5)):1106-1112 doi:10.1016/j.ajpath.2018.01.005.

    PMID: 29454754
  4. 4

    Spectrum of Papillary Breast Lesions According to World Health Organization Classification of Papillary Neoplasms of Breast.

    Hashmi AA, Faraz M, Rafique S, et al.

    Cureus 2020; (12(10)):e11026 doi:10.7759/cureus.11026.

    PMID: 33214954
  5. 5

    Treatment Strategy for Breast Benign Intraductal Papilloma: A Meta-Analysis.

    Lou C, Wang W, Zhou B

    Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 2024; (43(3)):39-49 doi:10.1615/JEnvironPatholToxicolOncol.2024052888.

    PMID: 38608144
  6. 6

    Pathologic High-risk Lesions, Diagnosis and Management.

    Murray M

    Clinical obstetrics and gynecology 2016; (59(4)):727-732 doi:10.1097/GRF.0000000000000234.

    PMID: 27681693
  7. 7

    Papillary lesions of the breast - review and practical issues.

    Ni Y, Tse GM

    Seminars in diagnostic pathology 2022; (39(5)):344-354 doi:10.1053/j.semdp.2022.06.001.

    PMID: 35718581
  8. 8

    Malignant upgrade rate and associated clinicopathologic predictors for concordant intraductal papilloma without atypia: A systematic review and meta-analysis.

    Keating N, Cevik J, Hopkins D, Lippey J

    Journal of surgical oncology 2024; (129(6)):1025-1033 doi:10.1002/jso.27592.

    PMID: 38305061
  9. 9

    The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034).

    Nakhlis F, Baker GM, Pilewskie M, et al.

    Annals of surgical oncology 2021; (28(5)):2573-2578 doi:10.1245/s10434-020-09215-w.

    PMID: 33047246
  10. 10

    Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis.

    Zhang X, Liu W, Hai T, Li F

    Annals of surgical oncology 2021; (28(13)):8643-8650 doi:10.1245/s10434-021-10188-7.

    PMID: 34331160
  11. 11

    Analysis of 612 Benign Papillomas Diagnosed at Core Biopsy: Rate of Upgrade to Malignancy, Factors Associated With Upgrade, and a Proposal for Selective Surgical Excision.

    Lee SJ, Wahab RA, Sobel LD, et al.

    AJR. American journal of roentgenology 2021; (217(6)):1299-1311 doi:10.2214/AJR.21.25832.

    PMID: 34008998
  12. 12

    High-Risk Breast Lesions on Core Biopsy: Rates of Upgrade and Management Recommendations.

    Grabenstetter A

    Surgical pathology clinics 2025; (18(4)):707-723 doi:10.1016/j.path.2025.05.001.

    PMID: 41224414
  13. 13

    The Management Strategy of Benign Solitary Intraductal Papilloma on Breast Core Biopsy.

    Ko D, Kang E, Park SY, et al.

    Clinical breast cancer 2017; (17(5)):367-372 doi:10.1016/j.clbc.2017.03.016.

    PMID: 28438672

This page is for informational purposes only and does not constitute medical advice. Your radiologist, pathologist, and breast specialist should interpret your biopsy and recommend surveillance or excision for your situation.